Esperion Stock Surges 57% as ARCHIMED Acquires Company for $1.1 Billion
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.
/ 1656 items
#XY↓
Moderna Beats Q1 2026 Revenue Estimates as International Sales Surge, Stock Jumps
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.
FDA Greenlights AUVELITY: First New Treatment for Alzheimer’s Agitation in Years
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
Eli Lilly Crushes Q1 Earnings and Raises 2026 Profit Forecast as Zepbound & Mounjaro Sales Explode
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Chiesi Buys KalVista for $1.9 Billion in Biggest Deal Yet to Strengthen Rare Disease Portfolio
Chiesi will buy KalVista for $1.9B to get EKTERLY, a new oral rare disease drug, and grow its global rare disease business.